(Q51233383)

English

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, pl

scientific article published on 27 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/28026912

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, pl (English)

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/28026912

1 reference

based on heuristic

inferred from title

Choon Hee Chung

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Chang Ho Ahn

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kyung Ah Han

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jae Myung Yu

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Joo Young Nam

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kyu Jeung Ahn

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Tae Keun Oh

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hyoung Woo Lee

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Dae Ho Lee

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jaetaek Kim

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Tae Sun Park

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Byung Joon Kim

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Seok Won Park

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hyeong Kyu Park

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kwang Jae Lee

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sang-Wook Kim

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jeong Hyun Park

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kwan Pyo Ko

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Chong Hwa Kim

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hyunjin Lee

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hak Chul Jang

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kyong Soo Park

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

27 December 2016

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/28026912

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

635-643

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Thiazolidinediones and fractures in men and women

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12866

21 January 2018

Identifiers

10.1111/DOM.12866

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28026912%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51233383&oldid=1234850507"